PathAI Receives FDA Clearance for AISight Dx Platform
PathAI has received FDA 510(k) clearance for its AISight Dx digital pathology platform, enabling its use in primary diagnosis.
PathAI has received FDA 510(k) clearance for its AISight Dx digital pathology platform, enabling its use in primary diagnosis.
NGS-based MRD testing offers unprecedented sensitivity and breadth in detecting low-frequency leukemic clones.
A study shows that saliva contains genetic markers linked to systemic diseases for a non-invasive alternative to blood-based diagnostics.
Bio-Rad Laboratories will showcase its latest clinical diagnostic solutions and host a QC workflow optimization workshop at ADLM 2025.
Juniper Genomics has launched publicly to offer a next-generation embryo screening platform that aims to improve IVF outcomes.